Friday, August 22, 2014 7:45:54 PM
All I have to say is "manages the clinical department budget..."
You mean Peregrine is going to have a budget soon?? : )
---------------------------------------
Associate Director/Director, Regulatory Affairs Reg Affairs Tustin, CA 07-Oct-2014 (PST) Full Time
Clinical Data Manager Clinical Affairs Tustin, CA 21-Sep-2014 (PST) Full Time
Clinical Trial Liaison Clinical OPS Tustin, CA 18-Oct-2014 (PST) Full Time
Clinical Trial Manager/Senior Manager Clinical OPS Tustin, CA 11-Sep-2014 (PST) Full Time
Director/Sr. Director, Clinical Research Clinical Affairs Tustin, CA 21-Oct-2014 (PST) Full Time -New!
Laboratory Assistant Lab OPS Tustin, CA 28-Sep-2014 (PST) Full Time
Manager, Data Governance Information Technology Tustin, CA 18-Oct-2014 (PST) Full Time -New!
Manufacturing Associate - Downstream Manufacturing Tustin, CA 14-Sep-2014 (PST) Full Time
Manufacturing Associate/Senior Associate Manufacturing Tustin, CA 14-Sep-2014 (PST) Full Time
Research Associate, Process Sciences Process Sciences Tustin, CA 24-Sep-2014 (PST) Full Time
Sr. Manager, Clinical Quality Assurance Quality Tustin, CA 12-Oct-2014 (PST) Full Time
Sr. Research Scientist - Pharmacology Pre-Clinical Tustin, CA 05-Oct-2014 (PST) Full Time
http://peregrineinc.applicantpro.com/jobs/
-------------------------------------------------------
Director/Sr. Director, Clinical Research
Date: Posted 22-Aug-2014, Closing 21-Oct-2014 (PST)
Department: Clinical Affairs
Location: Tustin, CA
Employment Type: Full Time
Peregrine Pharmaceuticals, on the list of Deloitte & Touche's 500 fastest growing North American technology companies, invites you to bring us your excellent hands-on clinical research management expertise and pharmaceutical industry experience to become part of our successful team. Peregrine has launched a Phase III lung cancer clinical trial for our lead drug therapy Bavituximab which has been given a fast-track designation by the FDA.
SUMMARY
The Director/Sr. Director, Clinical Research oversees the direction, planning, execution, and interpretation of clinical trials research and clinical operations. This role establishes and approves scientific methods for design and implementation of clinical protocols, data collection systems and final reports. The ideal candidate will have proven experience leading new and ongoing clinical research and clinical trials to ensure efficient and timely processing of confidentiality and clinical agreements. This key role interacts with investigational sites, clinical consultants, Contract Research Organizations and other vendors. We seek a dynamic experienced clinical team builder with strong abilities to select, develop, mentor and evaluate clinical personnel to ensure the successful and efficient operation of the department.
ESSENTIAL DUTIES AND RESPONSIBILITIES
Oversees and manages clinical development including the efficient planning and execution of clinical trials within established budget and timelines assuring all activities are in compliance with appropriate regulation.
Optimizes tactical and clinical value through global site selection.
Oversees adherence to protocols and determines study completion.
Directs internal and external resources to ensure timely patient recruitment, trial site selection, trial plan optimization and execution of quality trials.
Leads, manages and directly supervises employees in the Clinical Affairs department.
Responsible for interviewing, hiring, training and performance evaluation of employees.
Plans, assigns and directs the work of employees.
Oversees the development and implementation of SOP's for clinical research including SOP's for clinical trials and related activities.
Manages the clinical department budget and ensures the overall operation is within budget and timelines are agreed to in annual strategic goal setting.
Communicates regular updates to the management team on progress against timelines and budgets in support of all clinical projects.
Must be available to travel up to 30% domestically and internationally.
QUALIFICATIONS
A Master's degree, MD or PhD in the life sciences is preferred. We require a minimum of 12 years of pharmaceutical industry experience to include significant clinical research leadership roles. Extensive background in direct management, development and supervision of a clinical operations team is required. Oncology clinical trials experience is highly desirable.
RELOCATION AVAILABLE
Please note this position is based in Orange County, CA and is a full time onsite role. Competitive relocation assistance within the continental USA will be provided for well-qualified individuals.
EQUAL OPPORTUNITY/AFFIRMATIVE ACTION EMPLOYER
Peregrine Pharmaceuticals strongly supports and values the uniqueness of all individuals and promotes a work environment where diversity is embraced.
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!
Recent CDMO News
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
- Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 03/06/2024 09:31:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:57:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 12:34:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:39:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:38:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:37:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:36:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:35:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 12:56:02 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/08/2024 09:32:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:56:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:55:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:53:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:51:57 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 12/19/2023 09:05:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:34:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:33:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:32:11 AM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM